Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Background: Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneu- monia the most frequent cause of death in COVID-19 patients.